Literature DB >> 20306473

Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats.

Sushil K Jain1, Jennifer L Croad, Thirunavukkarasu Velusamy, Justin L Rains, Rebeca Bull.   

Abstract

Chromium and cysteine supplementation can improve glucose metabolism in animal studies. This study examined the hypothesis that a cysteinate complex of chromium is significantly beneficial than either of them in lowering blood glucose and vascular inflammation markers in Zucker diabetic fatty (ZDF) rats. Starting at the age of 6 wk, ZDF rats were supplemented orally (daily gavages for 8 more weeks) with saline-placebo (D) or chromium (400 microg Cr/Kg body weight) as chromium dinicocysteinate (CDNC), chromium dinicotinate (CDN) or chromium picolinate (CP) or equimolar L-cysteine (LC, img/Kg body weight), and fed Purina 5008 diet for 8 wk. ZDF rats of 6 wk age before any supplementations and onset of diabetes were considered as baseline. D rats showed elevated levels of fasting blood glucose, HbA(1), CRP, MCP-1, ICAM-1 and oxidative stress (lipid peroxidation) and lower adiponectin and vitamin C, when compared with baseline rats. In comparison to D group, CDNC group had significantly lower blood glucose, HbA(1), CRP, MCP-1, ICAM-1 and lipid peroxidation and increased vitamin C and adiponectin levels. CDN, CP or LC showed significantly less or no effect on these biomarkers. Only CDNC lowered blood creatinine levels in comparison to D. While CDN and CP had no effect, activation of NFkappaB, Akt and glucose transporter-2 levels were decreased, insulin receptor substrate 1 (IRS-1) activation increased in livers of CDNC-rats. CDNC effect on glycemia, NFkappaB, Akt and IRS-1 in liver was significantly greater compared with LC. Blood chromium levels did not differ between Cr-groups. Exogenous vitamin C supplementation significantly inhibited MCP-1 secretion in U937 monocytes cultured in high-glucose-medium. CDNC is a potent hypoglycemic compound with anti-inflammatory activity apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 and increased IRS-1 activation in livers of type 2 diabetic rats.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306473      PMCID: PMC3138725          DOI: 10.1002/mnfr.200900177

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  38 in total

Review 1.  Type 2 diabetes and atherosclerosis.

Authors:  R Donnelly; K R Davis
Journal:  Diabetes Obes Metab       Date:  2000-03       Impact factor: 6.577

Review 2.  Role of chromium in human health and in diabetes.

Authors:  William T Cefalu; Frank B Hu
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

3.  Chromium chloride inhibits oxidative stress and TNF-alpha secretion caused by exposure to high glucose in cultured U937 monocytes.

Authors:  S K Jain; K Kannan
Journal:  Biochem Biophys Res Commun       Date:  2001-12-07       Impact factor: 3.575

4.  Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis.

Authors:  M Langlois; D Duprez; J Delanghe; M De Buyzere; D L Clement
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

5.  Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes.

Authors:  S K Jain; R McVie; J Duett; J J Herbst
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

6.  Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men.

Authors:  Swapnil Rajpathak; Eric B Rimm; Tricia Li; J Steven Morris; Meir J Stampfer; Walter C Willett; Frank B Hu
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

Review 7.  Recent advances in the nutritional biochemistry of trivalent chromium.

Authors:  John B Vincent
Journal:  Proc Nutr Soc       Date:  2004-02       Impact factor: 6.297

8.  Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913.

Authors:  L O Ohlson; B Larsson; P Björntorp; H Eriksson; K Svärdsudd; L Welin; G Tibblin; L Wilhelmsen
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

9.  Akt is a downstream target of NF-kappa B.

Authors:  Fanyin Meng; Li Liu; Paul C Chin; Santosh R D'Mello
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157

Review 10.  Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease.

Authors:  Sonia Vega-López; Sridevi Devaraj; Ishwarlal Jialal
Journal:  J Investig Med       Date:  2004-01       Impact factor: 2.895

View more
  25 in total

Review 1.  Molecular mechanisms of chromium in alleviating insulin resistance.

Authors:  Yinan Hua; Suzanne Clark; Jun Ren; Nair Sreejayan
Journal:  J Nutr Biochem       Date:  2012-04       Impact factor: 6.048

2.  Controlling type-2 diabetes by inclusion of Cr-enriched yeast bread in the daily dietary pattern: a randomized clinical trial.

Authors:  Amalia E Yanni; Nikoleta S Stamataki; Panagiotis Konstantopoulos; Maria Stoupaki; Athanasios Abeliatis; Irene Nikolakea; Despoina Perrea; Vaios T Karathanos; Nikolaos Tentolouris
Journal:  Eur J Nutr       Date:  2016-10-12       Impact factor: 5.614

3.  Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways.

Authors:  Danqing Jing; Hua Bai; Shinan Yin
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

4.  Hyperketonemia decreases mitochondrial membrane potential and its normalization with chromium (III) supplementation in monocytes.

Authors:  Justin L Rains; Sushil K Jain
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

5.  Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study.

Authors:  Sushil K Jain; Gunjan Kahlon; Lester Morehead; Richa Dhawan; Benjamin Lieblong; Tommie Stapleton; Gloria Caldito; Robert Hoeldtke; Steven N Levine; Pat Farrington Bass
Journal:  Mol Nutr Food Res       Date:  2012-06-06       Impact factor: 5.914

6.  The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.

Authors:  Yen-Lin Chen; Jiunn-Diann Lin; Te-Lin Hsia; Frank Chiahung Mao; Chun-Hsien Hsu; Dee Pei
Journal:  Eur J Nutr       Date:  2013-03-14       Impact factor: 5.614

7.  Effects of combined dietary chromium(III) propionate complex and thiamine supplementation on insulin sensitivity, blood biochemical indices, and mineral levels in high-fructose-fed rats.

Authors:  Ewelina Król; Zbigniew Krejpcio; Sławomir Michalak; Rafał W Wójciak; Paweł Bogdański
Journal:  Biol Trace Elem Res       Date:  2012-10-16       Impact factor: 3.738

8.  Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2.

Authors:  Carlos Hierro; Maria J Monte; Elisa Lozano; Ester Gonzalez-Sanchez; Jose J G Marin; Rocio I R Macias
Journal:  Eur J Nutr       Date:  2013-05-26       Impact factor: 5.614

9.  Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro.

Authors:  Rituparna Ganguly; Amy M Wen; Ashley B Myer; Tori Czech; Soumyadip Sahu; Nicole F Steinmetz; Priya Raman
Journal:  Nanoscale       Date:  2016-03-28       Impact factor: 7.790

10.  Beneficial Effect of Bis(Hinokitiolato)Zn Complex on High-fat Diet-induced Lipid Accumulation in Mouse Liver and Kidney.

Authors:  Yuki Naito; Yutaka Yoshikawa; Katsuhiko Yoshizawa; Akiko Takenouchi; Hiroyuki Yasui
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.